AUXELLENCE
Health Corporation

Auxellence Closes $2.77 Million Debt and $165,000 Equity Financing

VANCOUVER, BC, Thursday April 7, 2016 – Auxellence Health Corporation (CSE:AID, OTCQB: AXHLF) "Auxellence" or the "Company" reports that it is has closed the current financing originally announced on February 22, 2016.

Under the terms of the financing the company:

1) arranged a one-year, $1.05 million credit facility through the Chairman and CEO as announced February 23, 2016;
2) resolved the Notice of Default and Demand for Payment for all outstanding amounts with its operator totaling approximately $827,681 as announced February 25, 2016 with a convertible debt note;
3) arranged convertible debt for $900,000 of the company's debt
4) closed on tranches of equity totaling $165,000 of subscriptions

The Company wishes to thank all parties for their support. Management can now actively and aggressively further developing the business by working the 2nd Stage of its Commercial Pilot trials of the Tulip(TM) Theranostic (Therapeutic & Diagnostic) Health System as previously announced December 23, 2015.

Contact:
Sydney Au, CEO
Auxellence Health Corporation
Email: ceo@auxellence.com
Phone: (604) 780-3311
Website: http://www.auxellence.com
CSE Micro-site: http://www.cnsx.ca/CNSX/Securities/Technology/Auxellence-Health-Corporation.aspx

About Tulip™
TULIP™ is a medical device cleared for sales in Canada and Europe as a blood pressure monitor with interactive protocols. The device enables physiologically interactive health apps useful in testing, tracking, and treating common health conditions. The online system is aimed primarily at "practicing patients" interested in normalizing blood pressure, blood glucose, and body weight. Session schedules, measurement procedures, and conditioning protocols are prescribed automatically by the system from extemporaneous data acquired from the user.

About Auxellence Health Corporation (CSE: AID, OTCQB: AXHLF)

AUXELLENCE

Health Corporation

Auxellence is a technology company engaged in the provision of medical monitoring, diagnostics, therapeutics and biomedical online services for common health problems. The company offers an extensive platform for physiologically interactive computing supporting therapeutic-diagnostic (theranostic) devices, expert systems, and recommender applications for personal health management. The initial focus is on weight management and skin conditions.

Disclaimer for Forward-Looking Information

Statements in this press release regarding the Company which are not historical facts are “forward-looking statements” that involve risks and uncertainties. Such information can generally be identified by the use of forwarding-looking wording such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated in such statements due to factors. The Company does not intend to update any changes to such statements, except as required by law. Although Management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. We seek safe harbour.

THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES